The traditional method of big batch manufacturing must change as companies move away from the one-size-fits-all blockbuster model toward more innovative, targeted biologics that deliver better outcomes.
Are you up to the task of bringing a biologic drug to market? Do you have a strategy and plan for moving forward? Here we explore, from a biopharma process development and manufacturing perspective.
Building a bioprocessing facility is usually a complicated process and requires partnering with not only drug developers, but also many different experts in various industries.
Why new biopharma processing technology and automated processing is key to driving down costs and boosting facility efficiency.
A growing number of biologic manufacturers are adopting new fill-finish technologies, including single-use systems, pre-filled syringes, and automated fill-finish systems. When doing so it is critical to also consider the cost-benefit tradeoffs.
Demand to increase speed and flexibility while maintaining sterility spurs the adoption of novel technologies and materials, all of which introduce new challenges.
Single-use technology is well-established and made its way into commercial licensed facilities, but there is more innovation in this field which will enhance its versatility into new markets and technologies.
The concept of optionality is key to staying flexible in biomanufacturing by keeping your options open and having multiple pathways to take while navigating through this highly uncertain environment.
Biopharma manufacturers seek dynamic processing economics that address the paradigm shift from blockbuster drugs with established production schemes to small-scale manufacturing and innovative tech.
The biosimilars market is suddenly booming, with established biopharma giants and nimble start-ups all clamoring for a piece of the action. But such steep competition means that only the wise will survive.
|
|
|
|
|
|
|
|
|